Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.51 |
| ▸ | HPN | P05981 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28394512 | 0.98 | KMT2A (0.54) | KMT2AKEAP1NFE2L2LMNANOTUM | |
| SCHEMBL27740406 | 0.85 | KMT2A (0.49) | KMT2AKEAP1NFE2L2LMNATP53 | |
| SCHEMBL5148009 | 0.83 | LMNA (0.51) | KMT2ALMNANOTUMKCNJ1KCNH2 | |
| SCHEMBL1269000 | 0.80 | KCNJ1 (0.68) | KMT2ALMNANOTUMKCNJ1KCNH2 | |
| SCHEMBL21152328 | 0.79 | NOTUM (0.72) | KMT2ALMNANOTUMTP53KCNJ1 | |
| SCHEMBL2627225 | 0.78 | NOTUM (0.59) | KMT2AKEAP1NFE2L2LMNANOTUM | |
| SCHEMBL22636960 | 0.76 | MAPT (0.57) | KMT2ALMNANOTUMKCNJ1KCNH2 | |
| SCHEMBL4456339 | 0.75 | KEAP1 (0.51) | KMT2AKEAP1NFE2L2LMNAHPN | |
| SCHEMBL3819681 | 0.75 | NOTUM (0.61) | KMT2ALMNANOTUMTP53SMN1; SMN2 | |
| SCHEMBL1743171 | 0.74 | KCNJ1 (0.45) | KMT2ALMNANOTUMKCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492220-B2 | Method for the preparation of oligonucleotides | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2025-12-09 | — | — | US | claimed |
| CN-116815222-A | Electrochemical DNA synthesis method based on titanium nitride material | 东南大学 | 2023-09-29 | — | — | CN | claimed |
| CN-116496326-A | Process for the preparation of oligomeric compounds | 南京金斯瑞生物科技有限公司 | 2023-07-28 | — | — | CN | claimed |
| US-20230192751-A1 | METHOD FOR THE PREPARATION OF OLIGONUCLEOTIDES | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (CA) | 2023-06-22 | — | — | US | claimed |
| CN-116180110-A | Electrochemical DNA synthesis method based on pulse direct-current voltage | 东南大学 | 2023-05-30 | — | — | CN | claimed |
| CN-116178468-A | 5' S-LNA nucleotides and oligonucleotides | 罗氏创新中心哥本哈根有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-109563121-B | 5' S-LNA nucleotides and oligonucleotides | 罗氏创新中心哥本哈根有限公司 | 2022-12-27 | — | — | CN | claimed |
| US-20220363706-A1 | 5`S-LNA nucleotides and oligonucleotides | HOFFMANN-LA ROCHE INC. | 2022-11-17 | — | — | US | claimed |
| US-11390641-B2 | 5′S-LNA nucleotides and oligonucleotides | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | claimed |
| US-20190292213-A1 | 5`S-LNA nucleotides and oligonucleotides | F. HOFFMANN-LA ROCHE AG (CH) | 2019-09-26 | — | — | US | claimed |
| EP-3491001-A1 | 5'S-LNA NUCLEOTIDES AND OLIGONUCLEOTIDES | Roche Innovation Center Copenhagen A/S (DK) | 2019-06-05 | — | — | EP | claimed |
| WO-2018019748-A1 | 5'S-LNA NUCLEOTIDES AND OLIGONUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-02-01 | — | — | WO | claimed |
| JP-57159711-A | — | — | None | — | — | JP | disclosed |
| US-12492220-B2 | Method for the preparation of oligonucleotides | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2025-12-09 | — | — | US | disclosed |
| EP-3728590-B1 | NOVEL THIOPHOSPHORAMIDITES | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2025-07-02 | — | — | EP | disclosed |
| EP-4547683-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | Alnylam Pharmaceuticals, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-1663204-A2 | C-KIT MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005020921-A2 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| CN-1249749-A | Phthalazinones | BYK GULDEN LOMBERC CHEM FAB GM (DE) | 2000-04-05 | — | — | CN | disclosed |
| JP-S57159711-A | LOW OXYGEN CELL SENSITIZER FOR RADIATION | OORUDO KIIHEIZU:KK | 1982-10-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292213-A1 | 5`S-LNA nucleotides and oligonucleotides | DHFR, NSUN3, NSUN2 | KMT2A 2245/4885KEAP1 3090/4885NFE2L2 2922/4885 |
| US-20220363706-A1 | 5`S-LNA nucleotides and oligonucleotides | DHFR, NSUN3, NSUN2 | KMT2A 2230/4885KEAP1 3209/4885NFE2L2 2983/4885 |
| US-11390641-B2 | 5′S-LNA nucleotides and oligonucleotides | NSUN3, NSUN2, DHFR | KMT2A 2136/4885KEAP1 3195/4885NFE2L2 2959/4885 |
| US-12492220-B2 | Method for the preparation of oligonucleotides | POLN, POLRMT, POLI | KMT2A 3340/4885KEAP1 3691/4885NFE2L2 3734/4885 |
| US-20230192751-A1 | METHOD FOR THE PREPARATION OF OLIGONUCLEOTIDES | POLN, POLRMT, POLI | KMT2A 3340/4885KEAP1 3691/4885NFE2L2 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.